Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies

• Published in: Annals of general psychiatry Vol. 20; no. 1; p. 41
• Main Authors: Murasaki, Mitsukuni, Inoue, Yoshifumi, Nakamura, Hiroshi, Kinoshita, Toshihiko
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.09.2021; BioMed Central; BMC
• Subjects: Adverse events; Antipsychotic drugs; Antipsychotics; Atypical antipsychotics; Blonanserin; Cognitive ability; Disease; Dopamine; Dopamine D3 receptor antagonist; Dosage and administration; Drug dosages; Drug therapy; Emotional behavior; Extrapyramidal system; Haloperidol; Illnesses; Long-term treatment; Medical students; Mental disorders; Pathogenesis; Patients; Polypharmacy; Psychosis; Psychotropic drugs; Review; Schizophrenia; Systematic review; Japan; Schizophrenia; Dopamine D3 receptor antagonist; Atypical antipsychotics; Blonanserin; Long-term treatment
• DOI: 10.1186/s12991-021-00361-3
• ISSN: 1744-859X

In general, the course of schizophrenia is chronic accompanied not only by positive and negative symptoms but also by cognitive dysfunction associated with psychosocial disability, and thus treatment combining antipsychotics and psychological therapy is considered promising. This review focused on two prospective, open-label, multicenter, phase 3 long-term studies for approval of oral blonanserin for the treatment of schizophrenia. These two studies included both inpatients and outpatients with variable disease duration or symptom prominence according to the Positive and Negative Syndrome Scale (PANSS). The selected two studies consisted of almost the same study schedule and eligibility criteria but different protocols regarding prior medications and concomitant antipsychotics. The proportion of patients who had a baseline PANSS negative score higher than the positive score was 82.2 and 67.2% in the two studies. In both studies, patients with an illness duration of ≥ 10 years were the most common. Based on the clinical symptoms at baseline, the physician determined the treatment: blonanserin monotherapy, blonanserin in combination with the existing antipsychotic medication, or therapy simplified to haloperidol together with blonanserin. The 28-week completion rate for long-term blonanserin treatment was high in both studies (82.2 and 78.7%). The types of adverse events in both studies were similar to those in the preceding 8-week randomized, active-controlled studies in Japan, which were included in the application package for the approval of oral blonanserin for patients with schizophrenia. Long-term blonanserin use did not increase the risk of extrapyramidal symptoms but reduced the dose of antiparkinsonian drugs, minimally affecting functioning. In both studies, the PANSS total score, positive score, and negative score were improved at the last observation carried forward compared with those at baseline. In conclusion, blonanserin is useful for long-term treatment of chronic schizophrenic patients when the appropriate management of clinical symptoms and adverse drug reactions are applied. Blonanserin might represent a promising treatment option that partially or completely relieves patients with chronic schizophrenia of polypharmacy. Blonanserin may possibly fit both the current real-world clinical setting and the currently recommended approach to antipsychotic medication.